[go: up one dir, main page]

SG161262A1 - Spiro-oxindole compounds and their uses as therapeutic agents - Google Patents

Spiro-oxindole compounds and their uses as therapeutic agents

Info

Publication number
SG161262A1
SG161262A1 SG201002513-8A SG2010025138A SG161262A1 SG 161262 A1 SG161262 A1 SG 161262A1 SG 2010025138 A SG2010025138 A SG 2010025138A SG 161262 A1 SG161262 A1 SG 161262A1
Authority
SG
Singapore
Prior art keywords
spiro
compounds
therapeutic agents
oxindole compounds
oxindole
Prior art date
Application number
SG201002513-8A
Other languages
English (en)
Inventor
Mikhail Chafeev
Sultan Chowdhury
Robert Fraser
Fu Jianmin
Rajender Kamboj
Hou Duanjie
Liu Shifeng
Mehran Seid Bagherzadeh
Serguei Sviridov
Sun Shaoyi
Sun Jianyu
Nagasree Chakka
Hsieh Tom
Vandna Raina
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of SG161262A1 publication Critical patent/SG161262A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG201002513-8A 2005-04-11 2006-04-11 Spiro-oxindole compounds and their uses as therapeutic agents SG161262A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67089605P 2005-04-11 2005-04-11

Publications (1)

Publication Number Publication Date
SG161262A1 true SG161262A1 (en) 2010-05-27

Family

ID=36952847

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002513-8A SG161262A1 (en) 2005-04-11 2006-04-11 Spiro-oxindole compounds and their uses as therapeutic agents

Country Status (30)

Country Link
US (4) US7700641B2 (fr)
EP (4) EP1888595B1 (fr)
JP (4) JP5118627B2 (fr)
KR (5) KR20150091542A (fr)
CN (2) CN102153562B (fr)
AR (1) AR056968A1 (fr)
AT (1) ATE543825T1 (fr)
AU (1) AU2006235593B2 (fr)
BR (1) BRPI0607926A2 (fr)
CA (3) CA2853635C (fr)
DK (1) DK1888595T3 (fr)
EC (1) ECSP077852A (fr)
ES (2) ES2488618T3 (fr)
HK (1) HK1199874A1 (fr)
HR (1) HRP20070505B1 (fr)
IL (1) IL186616A (fr)
MA (1) MA29684B1 (fr)
MX (1) MX2007012636A (fr)
MY (2) MY144968A (fr)
NO (1) NO20074619L (fr)
NZ (1) NZ561210A (fr)
PL (1) PL1888595T3 (fr)
PT (1) PT1888595E (fr)
RS (1) RS52295B (fr)
RU (1) RU2415143C2 (fr)
SG (1) SG161262A1 (fr)
SI (1) SI1888595T1 (fr)
TN (1) TNSN07382A1 (fr)
TW (1) TWI374141B (fr)
WO (1) WO2006110917A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) * 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
CN103271906A (zh) * 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
AU2007307638A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046087A2 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
CA2666136A1 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Derives spiro-oxindole tricycliques et utilisations de ceux-ci comme agents therapeutiques
WO2008046065A1 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spirohétérocycliques et utilisations de ceux-ci comme agents thérapeutiques
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
MX2010002938A (es) 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
EP2205079A4 (fr) 2007-10-04 2010-10-27 Merck Sharp & Dohme Dérivés d'oxindoline n-substituée comme bloqueurs des canaux calciques
US8273749B2 (en) * 2007-10-04 2012-09-25 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AU2014265116B2 (en) * 2008-10-17 2017-02-02 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (fr) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Dérivés de spiro-oxindole en tant que bloqueurs de canaux sodiques
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2015224493B2 (en) * 2009-06-29 2017-06-15 Xenon Pharmaceuticals Inc. Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (fr) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
BR112012021086A2 (pt) * 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
WO2012049555A1 (fr) 2010-10-13 2012-04-19 Lupin Limited Composés spirocycliques en tant que modulateurs de canaux sodiques dépendants du voltage
DK2655360T3 (da) 2010-12-21 2016-08-15 Bayer Ip Gmbh Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
RS55240B1 (sr) 2011-06-27 2017-02-28 Newron Pharm Spa Fluorisani derivati arilalkilaminokarboksamida
JP6125505B2 (ja) * 2011-09-06 2017-05-10 カッパーアールエヌエー，インコーポレイテッド 小分子による電位開口型ナトリウムチャネル・アルファサブユニット関連疾患の治療
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
WO2013154712A1 (fr) * 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Synthèses asymétriques de composés de spiro-oxindole utiles comme agents thérapeutiques
EP2935257B1 (fr) 2012-12-20 2018-02-07 Purdue Pharma LP Sulfonamides cycliques en tant que bloquants des canaux sodiques
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
TW201623264A (zh) 2014-03-29 2016-07-01 魯賓有限公司 作為電位閘控鈉通道調節劑之磺胺化合物
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP2017517555A (ja) 2014-06-12 2017-06-29 アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． 阻害剤ｐ５３−Ｍｄｍ２タンパク質−タンパク質相互作用としての、１，１’，２，５’−テトラヒドロスピロ［インドール−３，２’−ピロール］−２，５’−ジオン系を含む化合物
WO2016109795A1 (fr) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Funapide et difluorofunapide deutérés
WO2016127068A1 (fr) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Procédés de traitement d'une névralgie post-herpétique à l'aide d'une formule topique d'un composé de spiro-oxindole
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
SG11201804936UA (en) 2015-12-18 2018-07-30 Merck Sharp & Dohme Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP6898334B6 (ja) 2016-01-20 2021-07-28 ケモセントリックス，インコーポレイティド ２−オキシインドール化合物
AU2017283651B2 (en) 2016-06-16 2021-03-25 Xenon Pharmaceuticals, Inc. Solid state forms of spiro-oxindole compounds
WO2017218920A1 (fr) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Synthèse asymétrique de funapide
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
US11306100B2 (en) 2017-03-10 2022-04-19 Council Of Scientific & Industrial Research Spirooxindole compounds as GSK3B inhibitors and process for preparation thereof
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
CA3106239A1 (fr) 2018-07-27 2020-01-30 Biotheryx, Inc. Composes bifonctionnels agissant par agonisme sur des cdk
CN108976243B (zh) * 2018-08-23 2020-03-03 青岛农业大学 通过二甲基呋喃与含氧化吲哚邻羟基苄醇合成螺-色满-4,3′-氧化吲哚的合成方法
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
KR102662391B1 (ko) 2021-12-10 2024-05-03 원광대학교산학협력단 벤자제피노인돌 유도체 및 이의 제조 방법
CN116173015B (zh) * 2022-05-19 2024-09-20 四川大学 一种环己烯基异硫氰酸酯类化合物在制备Caspase-1抑制剂中的用途
CN115160331B (zh) * 2022-08-04 2023-06-02 青岛农业大学 一种氧化吲哚螺烯丙基取代色满骨架及其制备方法
CN116554185B (zh) * 2023-01-03 2025-07-08 中国科学技术大学 一种手性螺环氧化吲哚类化合物及其制备方法
CN119823139A (zh) * 2024-12-12 2025-04-15 武汉光化学技术研究院 一种手性螺环氧化吲哚类化合物及其合成方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) * 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
DE3019562A1 (de) * 1980-05-22 1981-11-26 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zum steuern einer brennkraftmaschine
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
JPS62194907A (ja) * 1986-02-21 1987-08-27 Bridgestone Corp 外観の改良された低転り抵抗ラジアルタイヤ
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
GB2205103A (en) * 1987-05-21 1988-11-30 Shell Int Research Modified block copolymers and process for the preparation thereof
EP0299914B2 (fr) * 1987-07-17 2003-04-23 Schering Aktiengesellschaft Dérivés de prostaglandines 9-halogène (Z), leur procédé de préparation et leur application thérapeutique
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
ES2110965T3 (es) 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
CA2095718A1 (fr) 1990-11-22 1992-05-23 Hans-Rudolf Waespe Derives d'acide isonicotinique et composes spiranniques apparentes, herbicides
US5116854A (en) 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH08503450A (ja) 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5278162A (en) 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
US5763471A (en) 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en) 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
CA2235686C (fr) 1995-10-24 2007-06-26 Sanofi Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE467418T1 (de) 1997-01-20 2010-05-15 Immodal Pharmaka Gmbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
EP1008588B1 (fr) * 1997-02-10 2003-04-16 Ono Pharmaceutical Co., Ltd. Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
DE69821987T2 (de) * 1997-12-25 2004-12-16 Ono Pharmaceutical Co. Ltd. Omega-cycloalkyl-prostaglandin e2 derivate
JP4087938B2 (ja) * 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
EE04548B1 (et) 1998-04-01 2005-10-17 Nortran Pharmaceuticals Inc. Aminotskloheksleeterhendid, nende kompositsioonid ja nende kasutamine
RU2233841C2 (ru) * 1998-06-12 2004-08-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Бета-карболиновые соединения, фармацевтические композиции на их основе и способы связывания, достижения агонистического/антагонистического эффекта
US20040038970A1 (en) * 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (fr) 1998-07-27 2000-02-10 Abbott Laboratories Antiproliferants a base d'oxazolines substituees
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
CA2373990C (fr) 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazines inhibiteurs de kinases
EP1399155B1 (fr) 1999-07-21 2008-05-28 Boehringer Ingelheim Pharmaceuticals Inc. Petites molecules utiles pour le traitement de maladies inflammatoires
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
JP4048053B2 (ja) 1999-11-26 2008-02-13 マクギル ユニバーシティー 特発性全身てんかんについてのローカス、当該ローカスのミューテーション、及びてんかんの評価、診断、予後、または治療のための当該ローカスの使用方法
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
EP1330426A4 (fr) 2000-10-13 2005-09-14 Bristol Myers Squibb Co Ouvreurs selectifs de canaux potassiques maxi-k, fonctionnant sous des conditions de concentration calcique intracellulaire elevee, procedes et utilisations associes
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
RU2233082C2 (ru) * 2001-06-26 2004-07-27 Институт животноводства УААН Регулятор вакуума доильного агрегата
JP2005507872A (ja) 2001-08-14 2005-03-24 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
EP1451173A4 (fr) 2001-11-01 2005-10-26 Icagen Inc Piperidines
WO2003037274A2 (fr) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides et -sulfonamides
EP1448560B1 (fr) 2001-11-20 2005-06-15 Eli Lilly And Company AGONISTES beta 3 A BASE D'OXINDOLE 3-SUBSTITUE
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
JP2005519921A (ja) 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003078394A1 (fr) 2002-03-15 2003-09-25 Eli Lilly And Company Derives de dihydroindol-2-one modulant le recepteur nucleaire de l'hormone steroide
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
CN1662206A (zh) 2002-06-25 2005-08-31 惠氏公司 硫代－2－羟基吲哚衍生物在治疗皮肤病中的用途
AU2003245637A1 (en) 2002-06-25 2004-01-06 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
CA2525866A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Traitement de troubles psychotiques et depressifs
CA2625837A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
MXPA05012392A (es) 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamientos de ansiedad con ziprasidona.
JP2007516955A (ja) 2003-05-16 2007-06-28 ファイザー・プロダクツ・インク 双極性障害および関連症候の治療
BRPI0412348A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piperazina e seu uso como agentes terapêuticos
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (fr) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
EP1557166A1 (fr) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur
US7507760B2 (en) * 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
BRPI0509307A (pt) 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
BRPI0509745A (pt) 2004-04-08 2007-09-25 Topotarget As compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer
WO2005104711A2 (fr) 2004-04-27 2005-11-10 Wyeth Purification de modulateurs de recepteur de progesterone
JP2007536283A (ja) 2004-05-05 2007-12-13 ユニバイオスクリーン エス．アー． ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2007537235A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
US20050288317A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
KR100944301B1 (ko) 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CN101166722A (zh) 2005-04-29 2008-04-23 惠氏公司 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法
WO2006125048A2 (fr) * 2005-05-16 2006-11-23 Gilead Sciences, Inc. Composes inhibant l'integrase
EP1924264B9 (fr) * 2005-09-01 2014-02-19 F.Hoffmann-La Roche Ag Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
CA2666136A1 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Derives spiro-oxindole tricycliques et utilisations de ceux-ci comme agents therapeutiques
AU2007307638A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046082A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés hétérocycliques comme agents thérapeutiques
WO2008046083A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
WO2008046065A1 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spirohétérocycliques et utilisations de ceux-ci comme agents thérapeutiques
WO2008117050A1 (fr) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazines pyrazolyl-amino substituées et utilisation de ces composés pour le traitement du cancer
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) * 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
WO2010078307A1 (fr) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Dérivés de spiro-oxindole en tant que bloqueurs de canaux sodiques
WO2010132352A2 (fr) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Composés spiro et leur utilisation en tant qu'agents thérapeutiques
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (fr) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos

Also Published As

Publication number Publication date
TW200720277A (en) 2007-06-01
EP3241834A1 (fr) 2017-11-08
JP5118627B2 (ja) 2013-01-16
AR056968A1 (es) 2007-11-07
RU2007141632A (ru) 2009-05-20
US7935721B2 (en) 2011-05-03
RS52295B (sr) 2012-12-31
TWI374141B (en) 2012-10-11
KR20140063803A (ko) 2014-05-27
TNSN07382A1 (en) 2009-03-17
EP2752417A1 (fr) 2014-07-09
SI1888595T1 (sl) 2012-05-31
HK1168104A1 (en) 2012-12-21
HK1199874A1 (en) 2015-07-24
ECSP077852A (es) 2008-01-23
JP2008535930A (ja) 2008-09-04
HRP20070505B1 (hr) 2014-12-19
ATE543825T1 (de) 2012-02-15
KR20160130864A (ko) 2016-11-14
MA29684B1 (fr) 2008-08-01
PL1888595T3 (pl) 2012-07-31
ES2381683T3 (es) 2012-05-30
EP2428515A1 (fr) 2012-03-14
DK1888595T3 (da) 2012-05-29
EP1888595A2 (fr) 2008-02-20
IL186616A0 (en) 2008-01-20
JP2014129422A (ja) 2014-07-10
KR101432460B1 (ko) 2014-08-21
NO20074619L (no) 2007-10-31
EP2752417B1 (fr) 2017-05-31
US20120122909A9 (en) 2012-05-17
HRP20070505A2 (hr) 2008-05-31
MX2007012636A (es) 2008-01-11
MY158766A (en) 2016-11-15
AU2006235593A1 (en) 2006-10-19
CN102153562A (zh) 2011-08-17
ES2488618T3 (es) 2014-08-28
WO2006110917A3 (fr) 2007-01-04
CA2853635A1 (fr) 2006-10-19
JP2016056212A (ja) 2016-04-21
RU2415143C2 (ru) 2011-03-27
EP2428515B1 (fr) 2014-05-07
MY144968A (en) 2011-11-30
KR20080007581A (ko) 2008-01-22
BRPI0607926A2 (pt) 2009-11-24
CA2853635C (fr) 2017-05-16
HK1161873A1 (en) 2012-08-10
IL186616A (en) 2017-09-28
NZ561210A (en) 2011-03-31
US8106087B2 (en) 2012-01-31
CN102153562B (zh) 2015-05-13
US20060252812A1 (en) 2006-11-09
EP1888595B1 (fr) 2012-02-01
KR20150091542A (ko) 2015-08-11
US20110251224A1 (en) 2011-10-13
AU2006235593B2 (en) 2012-07-05
CA2604115C (fr) 2014-11-04
EP2428515B9 (fr) 2014-09-17
JP2012246313A (ja) 2012-12-13
US7700641B2 (en) 2010-04-20
US20100125072A1 (en) 2010-05-20
KR20130089279A (ko) 2013-08-09
US20100130487A1 (en) 2010-05-27
KR101402557B1 (ko) 2014-05-30
WO2006110917A2 (fr) 2006-10-19
CA2604115A1 (fr) 2006-10-19
CN101184761A (zh) 2008-05-21
JP5548745B2 (ja) 2014-07-16
CA2956647A1 (fr) 2006-10-19
PT1888595E (pt) 2012-05-23

Similar Documents

Publication Publication Date Title
TNSN07382A1 (en) Spiro-oxindole compounds and their uses as therapeutic agents
TNSN07384A1 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
TW200833695A (en) Use of spiro-oxindole compounds as therapeutic agents
WO2008046087A3 (fr) Composés spiro et leurs utilisations en tant qu&#39;agents thérapeutiques
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
WO2008046084A3 (fr) Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2008094909A3 (fr) Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d&#39;affections induites par les canaux sodiques
WO2010045251A3 (fr) Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
TW200716596A (en) Substituted amide derivatives and methods of use
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2009003875A (es) Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3&#39;-indol)-2&#39; (1&#39;h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
WO2008147864A3 (fr) Procédés d&#39;utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
TW200833698A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2011047173A3 (fr) Compositions pharmaceutiques à usage oral
WO2010132352A3 (fr) Composés spiro et leur utilisation en tant qu&#39;agents thérapeutiques
WO2009140341A3 (fr) Compositions d&#39;atorvastatine
WO2008109856A3 (fr) Procédés de traitement de maladies ou d&#39;affections associées aux canaux à sodium au moyen de composés de type diazépinone.
WO2008101029A3 (fr) Procédés d&#39;utilisation de composés de thiazole, d&#39;oxazole et d&#39;imidazole dans le traitement de maladies ou d&#39;états provoqués par le canal sodique
WO2008039894A3 (fr) Compositions pharmaceutiques d&#39;atorvastatine
WO2008121859A8 (fr) Procédés d&#39;utilisation de composés tricycliques dans le traitement de maladies ou d&#39;affections véhiculées par canal sodique